BAM
HQL

Bruderman Asset Management’s abrdn Life Sciences Investors HQL Stock Holding History

Bruderman Asset Management’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-22
Closed – – 217
2016
Q4 		$0 Sell
22
-15
-41% -$263 ﹤0.01% 374
2016
Q3 		$1K Buy
37
+2
+6% +$38 ﹤0.01% 372
2016
Q2 		$1K Buy
+35
New +$646 ﹤0.01% 365

Other funds holding HQL

NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of Nova Scotia
Bank of Nova Scotia Toronto, Ontario, Canada $57.2B AUM 35.3% 1-Year Est. Return
Cohen & Steers
Cohen & Steers New York $57.6B AUM 8.03% 1-Year Est. Return

Bruderman Asset Management's HQL Position: Q1 2017 in Review

Bruderman Asset Management sold out of abrdn Life Sciences Investors (HQL) in Q1 2017, closing a stake of 22 shares.

Bruderman Asset Management first reported a position in HQL in Q2 2016 and held it in 3 quarters. The position peaked at $1K in Q3 2016. 41 funds tracked by Wall St. Rank hold HQL as of Q1 2017.

  • Bruderman Asset Management reported no remaining abrdn Life Sciences Investors position as of Q1 2017 after selling out during the quarter.
  • Bruderman Asset Management sold 22 abrdn Life Sciences Investors shares in Q1 2017.
  • Bruderman Asset Management first reported a position in abrdn Life Sciences Investors in Q2 2016 and held it in 3 quarters.
  • Bruderman Asset Management's abrdn Life Sciences Investors position peaked at $1K in Q3 2016.
  • 41 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q1 2017.

Based on Bruderman Asset Management's 13F filing for Q1 2017, filed 9 May 2017.